相关实验视频

Updated: Jun 28, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

在患有抗氨酸抑制剂耐药性FSGS的儿童中,Rituximab/Mycophenolate组合疗法

Saumil Gaur¹, Partha P Paul², Mounika Motamarri²

¹Consultant Paediatrician and Transplant Nephrologist, Rainbow Children Hospital, Marathahalli, Bangalore, Karnataka, India.

Indian journal of nephrology

|April 22, 2024

概括

双重治疗与rituximab和mycophenolate为儿童提供了一个有前途的治疗方法,卡尔西纽林抑制剂耐药的焦点细分结晶体硬化 (FSGS). 这种方法在大多数患者中成功地维持了缓解,在具有挑战性的儿科病中显示出有效性.

科学领域:

儿科脏病学儿科脏病学
免疫抑制疗法免疫抑制疗法
淋巴细胞疾病淋巴细胞疾病

背景情况:

儿童的焦点细分型血小板硬化 (FSGS) 具有有限的治疗选择,特别是CNI耐药的形式.
像塔克罗利和环素这样的氨酸抑制剂 (CNIs) 是标准的,但并不普遍有效.
对于对CNI治疗无反应的儿科FSGS需要新的策略.

研究的目的:

评估双重治疗方案在患有CNI耐药FSGS的儿童中的疗效.
评估Rituximab和mycophenolate联合治疗维持缓解的能力.
分析这种特定儿科患者群体的治疗结果和安全性.

主要方法:

对13名患有CNI耐药FSGS的儿童进行了回顾性分析.
治疗涉及与rituximab和mycophenolate的双重治疗至少1年.
测量结果包括持续缓解,功能和不良事件.

主要成果:

84.6%的儿童在双重治疗后的一年内实现了持续缓解.
该疗法在类固醇依赖和类固醇耐药的FSGS病例中都有效.
没有报告任何不良反应或感染,功能得到保护.

结论:

双重的rituximab和mycophenolate治疗是一种有前途且有效的策略,用于对CNI耐药的儿科FSGS.
这种组合可以在绝大多数接受治疗的儿童中实现持续缓解.
该疗法表现出良好的安全性,并保留了功能.

关键词:

卡尔西纽林抑制剂耐药性卡尔西纽林抑制剂耐药性这些都是FSGS,FSGS,FSGS.基酸盐是什么基酸盐是什么这就是Rituximab.

更多相关视频

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...